Drug Type Shared antigen vaccine, Therapeutic vaccine |
Synonyms Ad5 [E1-, E2b-]-HER2/neu Vaccine, ETBX 021 |
Target |
Action modulators |
Mechanism HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | United States | 28 Sep 2018 | |
Metastatic Pancreatic Cancer | Phase 2 | United States | 01 Aug 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | - | 01 Feb 2018 | |
Ovarian Epithelial Carcinoma | Phase 2 | - | 01 Dec 2017 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | - | 01 Dec 2017 | |
Transitional Cell Carcinoma | Phase 2 | - | 01 Dec 2017 | |
Pancreatic Cancer | Phase 2 | - | - | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | United States | 04 Mar 2017 |
Phase 1 | 3 | zsbsuipspi = scfmwwkjye ciaxpmezdr (amhlwexigp, xnhbmozcng - rxqmphzgmf) | - | 13 Jan 2025 | |||
Phase 1/2 | 2 | SBRT+Aldoxorubicin Hydrochloride+GI-6301+GI-4000+ETBX-061+Cetuximab+ETBX-051+ETBX-011+5-fluorouracil+ALT-803+ETBX-021+Nab-paclitaxel+Cyclophosphamide+Avelumab+haNK+Leucovorin+GI-6207+Regorafenib+oxaliplatin+Capecitabine (NANT Colorectal Cancer (CRC) Vaccine) | yxupebntjd = tefzxfznbx gnemmnxxup (nylxvojiku, twnshugyzx - kmcjusoamz) View more | - | 11 Dec 2024 | ||
(Regorafenib) | gptodvsdbi(kvbctdswlf) = cgqszlntsy bbyjnhvimg (imjtpxguim, lbpgpcrbka - hhoajgqbje) View more |